Harnessing Hazara Virus as a Surrogate for Crimean–Congo Hemorrhagic Fever Virus Enables Inactivation Studies at a Low Biosafety Level
Pathogens · 2025
DOI: 10.3390/pathogens14070700 ↗Kurz gefasst
Fachartikel in der Zeitschrift Pathogens, 2025. Verfasst von Judith Olejnik und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Virology, Immunology and Microbiology, Chobanian & Avedisian School of Medicine, Boston University, Boston, MA 02118, USA. Hauptthemen laut MEDLINE: Hemorrhagic Fever Virus, Crimean-Congo, Virus Inactivation, Containment of Biohazards, Nairovirus. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 67 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIAID NIH HHS, Elizabeth R. Griffin Program,, NIH HHS.
Abstract (Originalsprache)
Research on highly pathogenic biosafety level 4 (BSL-4) viruses that are classified as Select Agents involves transferring inactivated materials to lower containment levels for further analysis. Compliance with Select Agent and BSL-4 safety regulations necessitates the validation and verification of inactivation procedures. To streamline this process, it would be beneficial to use surrogate BSL-2 viruses for inactivation studies. This not only simplifies BSL-4 work but also enables the testing and validation of inactivation procedures in research facilities that lack access to high-containment laboratories yet may receive samples containing highly pathogenic viruses that require efficient and complete inactivation. In this study, we used Hazara virus (HAZV) as a surrogate virus for Crimean–Congo hemorrhagic fever virus to show the efficacy of various inactivation methods. We demonstrate the successful inactivation of HAZV using TRIzol/TRIzol LS and aldehyde fixation. Importantly, the parameters of the aldehyde inactivation of cell pellets differed from those of the monolayers, highlighting the importance of inactivation validation. As part of this study, we also defined specific criteria that must be met by a BSL-2 virus to be used as a surrogate for a closely related BSL-4 virus. Defining these criteria helps identify suitable nonpathogenic surrogates for developing inactivation procedures for highly pathogenic viruses.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Virology, Immunology and Microbiology, Chobanian & Avedisian School of Medicine, Boston University, Boston, MA 02118, USA.
- National Emerging Infectious Diseases Laboratories (NEIDL), Boston University, Boston, MA 02218, USA.
- Center for Regenerative Medicine (CReM), Boston University and Boston Medical Center, Boston, MA 02118, USA.
ORCID-Profile: Judith Olejnik, Kristina Meier, Elizabeth Y Flores, Adam J Hume, Elke Mühlberger
Förderung
- NIAID NIH HHS
- Elizabeth R. Griffin Program,
- NIH HHS
- National Institutes of Health, National Institute of Allergy and Infectious Diseases
- Elizabeth R. Griffin Program
Zitieren
APA
Olejnik, J., Meier, K., Herrera, J. N., DeStasio, D. J., Deeney, D. J., Flores, E. Y., White, M. R., Hume, A. J., & Mühlberger, E. (2025). Harnessing Hazara Virus as a Surrogate for Crimean–Congo Hemorrhagic Fever Virus Enables Inactivation Studies at a Low Biosafety Level. Pathogens. https://doi.org/10.3390/pathogens14070700
Vancouver
Olejnik J, Meier K, Herrera JN, DeStasio DJ, Deeney DJ, Flores EY, et al. Harnessing Hazara Virus as a Surrogate for Crimean–Congo Hemorrhagic Fever Virus Enables Inactivation Studies at a Low Biosafety Level. Pathogens. 2025. doi:10.3390/pathogens14070700
BibTeX
@article{Olejnik2025,
author = {Olejnik, Judith and Meier, Kristina and Herrera, Jarod N and DeStasio, Daniel J and Deeney, Dylan J and Flores, Elizabeth Y and White, Mitchell R and Hume, Adam J and Mühlberger, Elke},
title = {Harnessing Hazara Virus as a Surrogate for Crimean–Congo Hemorrhagic Fever Virus Enables Inactivation Studies at a Low Biosafety Level},
journal = {Pathogens},
year = {2025},
doi = {10.3390/pathogens14070700}
}
EUVIMED